Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | BCR | P11274 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 7/20 | 0.32 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050676 | 1.00 | ABL1 (0.36) | ABL1BCRKRASCYP8B1KDM4E | |
| SCHEMBL21050764 | 1.00 | ABL1 (0.36) | ABL1BCRKRASCYP8B1KDM4E | |
| SCHEMBL21050944 | 0.96 | ABL1 (0.36) | ABL1BCRKRASCYP8B1KDM4E | |
| SCHEMBL21050918 | 0.93 | ABL1 (0.36) | ABL1BCRKRASCYP8B1PDGFRB | |
| SCHEMBL21050673 | 0.88 | ABL1 (0.38) | ABL1BCRKRASCYP8B1PDGFRB | |
| SCHEMBL21099361 | 0.87 | MET (0.39) | CYP8B1ALDH1A1 | |
| SCHEMBL21099203 | 0.87 | MET (0.39) | CYP8B1ALDH1A1 | |
| SCHEMBL21137316 | 0.87 | MET (0.39) | CYP8B1ALDH1A1 | |
| SCHEMBL21052452 | 0.87 | PDGFRB (0.33) | KRASCYP8B1KDM4ECUL4APDGFRB | |
| SCHEMBL21050711 | 0.87 | PDGFRB (0.33) | KRASCYP8B1KDM4ECUL4APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | ABL1 84/4885BCR 1121/4885KRAS 272/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | ABL1 84/4885BCR 1121/4885KRAS 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.